Suven Life Sciences Ltd Presenting the Positive Pharmacology Data of 4 NCEs at Society For Neuroscience (SFN-2013) Annual Meeting at San Diego, USA

Published: Nov 08, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HYDERABAD, INDIA (Nov 8, 2013) – Suven Life Sciences is presenting positive pharmacology data of 4 advanced molecules from their portfolio of investigational neuroscience new chemical entities (NCEs) at SFN 2013 to be held at San Diego, USA during 9-14, 2013. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this conference.

Key pharmacology, ADME and Safety data on selected NCEs, SUVN-G3031 (Histamine-3 receptor antagonist), SUVN-911 (Nicotinic acetylcholine alpha-4-beta-2 receptor antagonist), SUVN-D4010 (5-HT4 receptor partial agonist), SUVN-512 (5HT6 antagonists), CB2 agonist and M! modulators to treat the unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer’s, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain would be presented by Suven scientists at SFN-2013. These data presentations highlight Suven’s continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets and address a market size of more than $30 billion.

During SFN-2013 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore integrated collaborative research programs (CRP) and also Drug Discovery and Development Support Services (DDDSS) in addition to continued discussions with global pharma majors regarding their clinical candidate SUVN-502.

Suven is committed to neuroscience research and development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven’s CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders, Sleep, Neurodegeneration, Obesity and Pain through CNS targets.

For more information please visit our Web site at

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Help employers find you! Check out all the jobs and post your resume.

Back to news